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Abbreviations  
ALA : alpha linolenic acid 
ANSES : Agence Nationale pour la Sécurité et la Santé 
BDNF : Brain Derived Neurotrophic Factor 
DHA : docosahexaenoic acid 
EPA : eicosapentaenoic acid - IFSSAL :  
LA : linolenic acid 
MCAO : middle cerebral artery occlusion 
PUFA : polyunsaturated fatty acids  
SNAP-25 : Synaptosomal-Associated Protein 25 
VAMP-2 : Vesicle-Associated Membrane Protein 2 
VGLUT1 : Vesicular Glutamate Transporter 1 
VGLUT2 : Vesicular Glutamate Transporter 2 
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Abstract: 
Stroke is a worldwide main cause of mortality and morbidity. Most of the preventive and 
neuroprotective treatments identified in preclinical studies failed in clinical trials. Although 
there is a consensus that nutrition is important for health, its role is underestimated in stroke. 
Indeed an increase consumption of salt and fatty foods may promote hypertension and 
obesity, which are well known risk factors of stroke. In contrast it is more difficult to identify 
a risk factor arising from a deficiency in an essential nutrient in the diet. Western modern 
diets are deficient in omega-3 polyunsaturated fatty acids, which are essential for brain health. 
Such deficiency may constitute by itself a risk factor for stroke. Furthermore, an imbalance in 
the consumption of omega-6 and omega-3 progressively took place in the past 40 years 
leading to omega-6/omega-3 ratios that are far above the WHO healthy recommendations. A 
consequence of this imbalanced ratio has been the fostering of elevations in and increased 
prevalence of inflammatory cardiovascular diseases and obesity. In this context, this review 
outlines a promising therapeutic opportunity by integrating a nutritional-based approach 
focusing on omega-3 alpha-linolenic acid as nutraceutical to prevent the devastating damage 
caused by stroke. 
Keywords: 
stroke - brain ischemia - neuroprotection - omega-3 polyunsaturated fatty acids - alpha-
linolenic acid - synaptogenesis - neurogenesis - nutraceutical - enriched diet  
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Introduction  
Stroke is a worldwide main cause of mortality and morbidity. It causes a significant 
socioeconomic cost and a marked increase in patient/family burden. More than 1000 
molecules have demonstrated brain-protective properties in experimental models. More than 
200 clinical trials have examined neuroprotection for ischemic stroke, arguably despite 
sufficiently persuasive pre-clinical justification. To date most of the preventive treatments and 
neuroprotective drugs identified in preclinical studies failed in clinical trials. Therefore testing 
alternative protective strategies to prevent stroke is of considerable importance. Although 
there is a consensus that nutrition is important for health, its role is underestimated in stroke 
prevention. It is recognized that an increase consumption of salt, fatty foods and alcoholic 
beverages may promote pathologies like hypertension, obesity and alcoholism, all of which 
are well known risk factors of stroke. In contrast it is more difficult to identify a risk factor 
arising from a deficiency in an essential nutrient in the diet. Western modern diets are 
deficient in omega-3 polyunsaturated fatty acids, which are essential for brain health. Such 
deficiency constitutes by itself a risk factor for cardiovascular and cerebral diseases, including 
coronary heart disease and stroke. Furthermore, an imbalance in the consumption of omega-6 
and omega-3 PUFAs progressively took place in the past 40 years leading to omega-6/omega-
3 ratios that are far above the WHO healthy recommendations. A consequence of this 
imbalanced ratio has been the fostering of elevations in and increased prevalence of 
inflammatory cardiovascular and neuronal diseases and obesity. In this context, nutritional 
products with health benefits represent a growing interest. Functional foods enriched in 
omega-3 polyunsaturated acids or omega-3 used as nutraceuticals may reduce the frequency 
of strokes through preservation of both arterial and neuronal function. This review outlines a 
promising therapeutic opportunity by integrating a nutritional-based approach focusing on 
enriching the omega-3 alpha-linolenic acid (ALA) to prevent the devastating damage caused 
by stroke. 
1. Stroke statistics and healthcare 
1.1. Stroke statistics 
Stroke is the third leading cause of mortality and disability in the world. It has been predicted  
that stroke will account for 6.2% of the illness total burden in the first nine years in 2000 [1]. 
The mortality rate at five years is approximately 50% and a stroke strikes every 40 seconds 
with one death every four minutes [2,3]. The total number of stroke deaths is estimated at 
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508,000 per year in European Union; among the elderly population of 15 European countries, 
surveys showed 2,700,000 prevalent cases, and 536,000 incident cases each year [4]. In the 
United States, data show a total of 5,800,000 prevalent stroke cases, with 780,000 being first 
occurrences or recurrent strokes expected each year. Stroke causes many impairments and 
half of stroke survivors are left to live with physical or cognitive disabilities. This gives rise to 
real issues with hospital organization, care and public health, invariably exerting a high cost 
and a burden to society and health systems [5]. Because stroke compromises patients‟ lives so 
severely, they will require high levels of assistance and support even for common daily 
activities, which in turn directly impacts their quality of life - and their supporters. Therefore, 
those indirect costs contribute to increase the economic burden associate with stroke. The 
total economic costs (direct and indirect cost) for stroke were estimated at $73.7 billion in 
2010 [3]. The only current therapy against stroke is thrombolysis, which is provided only 
given to ~5% of patients because of 1) its numerous side effects, the major one being a 6-7%  
risk of bleeding [6] and; 2) the therapeutic window of 3 to 4.5 hours required to obtain a 
therapeutic effect of the thrombolytic [7]. Generally, the majority of patients are not treated 
with rtPA because they arrive after that narrow time window of treatment of opportunity, 
leaving clinicians without any repertoire of therapeutic opportunities. It is somewhat ironic 
that clot busters is considered the best „neuroprotectant‟, given that it mediates its effect 
through the vasculature, as opposed to exerting any direct protection in neurons. In a 
landmark analysis published in 2006, none of the 114 treatments (from more than a thousand  
treatments demonstrating neuroprotection against acute stroke since the 1960s at the 
preclinical level) achieved neuroprotection in clinical trials [8]. In addition, these drugs 
displayed poor adherence to the STAIR criteria (Stroke Therapy Academic Industry 
Roundtable), designed to increase the rigor by which neuroprotective agents were assessed at 
the preclinical level, in order to improve the odds of success in clinical trials [9]. This failure 
in translation from experimental models to clinical trials led to a major exodus of 
pharmaceutical companies from stroke, and also prompted a major re-evaluation of properties, 
which would constitute the „„best-in class‟‟ therapeutics to be used against stroke, integrating 
several aspect of the pathology of stroke. 
 
1.2. Stroke physiopathology 
An ischemic stroke is the result of an occlusion within a blood vessel supplying blood to the 
brain. This type of stroke accounts for more than ~80% of all stroke cases. The current 
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understanding of its pathophysiology has dramatically evolved over the past two decades 
mainly due to the animal studies. It is well known that the clot may either be formed locally in 
a small artery or may arise from the heart or from an injury in the wall of one of the cervical 
arteries (carotid and vertebral arteries). Occlusion of the middle cerebral artery (MCA) is one 
of the most widely used experimental models. Interruption of blood flow generated a 
hypoperfusion in the MCA territory that leads to a rapid decline in oxygen (hypoxia) and 
nutriments (glucose, ATP, energetic metabolites…). The cut off the supply of oxygen and 
glucose prevents the brain from generating the ATP needed to support its considerable energy 
demands. After focal ischemia, this energy deficit is most severe in the core of the ischemic 
territory that displays the lowest residual flow, wherein cell death occurs rapidly. In the core 
periphery, termed ischemic penumbra, even if reduced collateral blood flow buffers the full 
effects of stroke, waves of peri-infarct depolarization lead to neurotransmitter release. In 
concert with impairment of glial reuptake, extracellular glutamate achieves neurotoxic 
concentrations. Within the entire ischemic territory, glutamate overload into the extracellular 
space results in an hyperactivation of its receptors (excitotoxicity) leading to accumulation of 
intracellular Ca
2+
, which in turn sets off deleterious events including activation of lytic 
enzymes, mitochondrial dysfunction, and oxidative stress [9-11]. Irreversible damages are 
caused to neuronal membrane and compromise brain tissue survival. Initiation of these 
pathologic pathways differs in space and time (Figure 1) and also depends of the cellular 
subtype (neuronal or vascular, for example) [12].  
Historically, stroke research aimed to target one element of the deleterious cascade that takes 
place during stroke [8].  It failed to identify and validate an effective drug able to protect the 
neurovascular unit. Although restoration of cerebral blood flow can be successfully applied in 
a small 5% subset of patients by recombinant tissue plasminogen activator, there is still no 
therapeutic for stroke, underlining a pressing need to investigate additional strategies. 
Epidemiologic studies have demonstrated most patients presenting with a stroke possessed at 
least one risk factor. In addition, the pre-existence of certain risk factors in the patient history 
may worsen stroke outcome and compromises seriously post-stroke rehabilitation. These risk 
factors may also compromise also the patient eligibility to thrombolysis therapy [13]. 
Therefore, prevention of risk factors is one of the emerging axes of stroke care. 
1.3. Stroke, risk factors and nutrition 
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Severable modifiable and non-modifiable risk factors for ischemic stroke have been 
identified. Non-modifiable and irreversible risk factors include age, gender, ethnicity, and 
heredity. Among modifiable risk factors are hypertension, hypercholesterolemia, alcohol, 
smoking, atrial fibrillation, obesity and diabetes, which are in constant progression in all 
industrialized countries. The coexistence of modifiable risk factors has been estimated at up to 
80% of stroke incidence [14]. It is worth noting that modifiable risk factors of stroke often 
coexist with improper life-style and poor nutrition, causing imbalances in essential vitamins 
and nutriments, such as polyunsaturated fatty acids (PUFA) from the omega-3 family. Many 
clinical and epidemiologic studies have shown that insufficient dietary intake of fruits and 
vegetables causing deficiencies in vitamins, nutrients, and essential omega-3 polyunsaturated 
fatty acids (PUFAs) may be risk factor for cardiovascular and cerebral diseases, including 
stroke [15]. It is now clear that the evolution of human diet and the modernization of food 
manufacturing processes account for most of the essential nutrient deficiencies in our diet. As 
an example, the western diets provide an excessive quantity of omega-6 at the expense of 
omega-3. In the majority of the adult population of developed countries, omega-3 intake is far 
below the recommended Dietary Reference Intake, while consumption of omega-6 is more 
than 10 times higher than for omega-3. Consequently, the reported omega-6/omega-3 ratio is 
often above 10-15, compared to a ratio of approximately 5 recommended by most of the 
international Health organizations [16]. This elevated ratio represents strong evidence of an 
imbalance in the intake of these two families of essential fatty acids. Several epidemiologic 
studies demonstrated beneficial effects of diets enriched in omega-3 on various cerebral 
diseases,, also suggesting that they may reduce the risk of stroke. Meanwhile, the few 
preclinical studies that addressed their potential protective role against stroke-induced damage 
suggest that the nutraceutical potential of omega-3 could be a field of study of potentially 
major relevance. Altogether it emphasizes the need to focus more closely on the members of 
the omega-3 family and their nutraceutical potential in stroke. 
2. Why the polyunsaturation matter in omega-6 and omega-3 
2.1. Omega-6/ omega-3 structure 
Omega-3 and omega-6 PUFA families are structurally similar, with both containing a carbon 
long chain linked to hydrogen atoms punctuated by double bonds (unsaturation) and 
terminated by an acidic group. The conventional nomenclature differentiates the chemical 
structure of omega-3 and omega-6 by the location of the first double bond that is marked from 
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the methyl-terminal extremity. All fatty acids contain their first double bound between the 6
th
 
and 7
th
 carbon atoms in the omega-6 family, and between the 3
rd
 and 4
th
 carbon atom in the 
omega-3 fatty acids. Mammals cannot synthesize alpha-linolenic (ALA, C18:3ω3) and 
linolenic (LA, C18:2ω6) acids, which are PUFA omega-3 and omega-6 families precursors, 
respectively. By analogy with essential amino acids, ALA and LA are essential fatty acids and 
have to be supplied by the diet [17]. LA metabolism leads to the production of arachidonic 
acid (AA, C20:4 n-6) and docosapentaenoic acid (C22:6 n-6). ALA is successively 
transformed to eicosapentaenoic acid (EPA, C 20:5 n-3) which converts to docohexaenoic 
acid (DHA, C22:6 n-3). In mammals, the same enzymes (desaturases and elongases) 
participate in the synthesis of omega-3 and omega-6 long chain PUFA (figure 2). This results 
in a competition between both families to access the enzymatic pathway. The bioconversion 
rate of ALA to EPA and DHA is extremely low, accounting for why the omega-3 long chain 
are also considered as practically essential since they are almost all supplied by the diet [18]. 
Thus, any excess in LA intake may compromise EPA and DHA bioconversion from ALA. 
Moreover, enzymes involved in the metabolism of LA and ALA (elongases and desaturases) 
have a high preference for LA [19]. Their activity is inhibited by risk factors for stroke such 
as sugar, alcohol, saturated fat, aging and diabetes that are all well described. Therefore, any 
change in our diet, especially in the diary intake of LA and ALA impacts the ratio omega-
6/omega-3, raising concerns of omega-3 levels being too low to support protection or 
resistance against disease development. It is acknowledged that omega-6 and omega-3 fatty 
acids should be consumed in a balanced manner, from a variety of sources  (vegetal and 
animal fats). Recommendations made based on epidemiologic studies insist on the necessity 
restoring the balance omega-6/omega-3 to a ratio of 5:1. Hence, the need for a diet enriched in 
the different categories of omega-3 seems necessary to assure adequate intake of essential 
fatty acids to restore that balance. 
The large availability and the low cost of food sources containing trans fatty acids that are 
now recognized as detrimental to health facilitate their consumption in excess. In the same 
vein, human major food sources of PUFAs are omega-6-rich and omega-3-poor. Moreover, 
the nature of the omega-3 source shapes the content in omega-3 PUFAs. Animal sources that 
are rich in omega-3 are mostly fish. They provide EPA and DHA and display an omega-
6/omega-3 ratio extremely favorable to omega-3. Although animal sources could be used to 
counteract an unbalanced diet, they are often deprived of ALA. On the contrary vegetable 
sources of omega-3 may be rich in ALA but not in EPA and DHA and only linseed, rapeseed 
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and walnut oils furnish an omega-6:omega-3 ratio corresponding to the WHO 
recommendations (inferior to 5, Table 1).  ALA is found in diets enriched in vegetable such as 
red kidney beans and lima beans. Vegetable oil is one of the most important sources of PUFA 
(Table 1). However, several of the most commonly used oils have very low levels of PUFA 
(e.g. palm oil) and often very low levels of ALA (e.g. sunflower oil, sesame oil, and palm oil) 
[20]. 
2.2. The omega-3 family: DHA and EPA versus ALA supplementation 
Although the term nutraceutical is commonly used in marketing, it has no regulatory 
definition. According to DeFelice, who first proposed the term coined from “nutrition” and 
“pharmaceutical”, nutraceutical can be defined as a food (or food extract) that provides 
medical or health benefits, including the prevention and/or treatment of a disease. As 
compared to functional food or dietary supplements that support the body with the required 
amount of vitamins, fats, proteins, carbohydrates, etc, needed for its proper functioning, 
nutraceutical, which may be used in functional food or supplements should also have a proven 
efficiency preventing and/or treating disease [21]. The current approach to establish the 
efficacy of nutraceutical or nutritional interventions suffers from several limitations. We 
believe for clarity sake, that the used of nutraceutical may be restricted to compound isolated 
or purified from foods, and that could be used in medicinal forms. In this context, the interest 
for omega-3 as a nutraceutical has been focused mainly on long chain PUFA, EPA and DHA 
more than their precursor, ALA. Several reasons support this trend. A major reason is that 
ALA bioconversion to DHA seems very limited, with many studies reporting that conversion 
efficiency from ALA to its immediate metabolite EPA is 0.4% and the overall efficiency of 
conversion to DHA is less than 0,1% [22,23]. Diet supplementation with high levels of ALA 
leads to small increases in EPA (5%) as compared to supplementation with preformed EPA 
that is approximately 15-fold more efficient [18]. Barcelo-Coblijn and Murphy (2009) 
published a detailed review which examined publications studying conversion of ALA to 
EPA and DHA. Their conclusion was that exclusive consumption of ALA could not fulfill 
DHA requirements [24]. It is also often suggested that EPA and DHA combination may be 
more efficient in reducing the cardiovascular risk effect than ALA [25,26]. But, as shown in 
numerous studies, ALA exerts identical effects as DHA in different physiological processes, 
although longer periods and higher amounts of consumption of ALA are probably required 
[24]. Unfortunately, while most of the studies reported biophysical and functional properties 
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of DHA and EPA, intrinsic properties of ALA have not been  highlighted and its potential as 
nutraceutical, a field of study of potential major relevance has been inadequately addressed.  
2.3. Beneficial effects of ALA: the origin of the concept 
The pioneering studies of Tinoco and colleagues demonstrated important functions of ALA in 
animals. ALA deficiency in rat alimentation over several generations causes vision and brain 
function impairments [27]. Since that point, some in vitro and in vivo studies examining the 
effect of ALA on neurons directly demonstrated its potential against glutamate-mediated 
excitotoxicity, a neurodestructive phenomenon shared by many acute and chronic 
neurodegenerative diseases including epileptic seizures, acute spinal cord injury (SCI) and 
stroke [15]. In an experimental model of SCI in rats, ALA treatment 30 min before trauma 
reduced lesion size by 45% and improved neuronal survival and locomotor activity measured 
one week after injury [28]. The beneficial effects of ALA on function, neuronal/glia survival 
and biochemical marker in various SCI models were reviewed in animals subjected to SCI 
[29,30]. In a model of epilepsy induced by kainate administration, a powerful activator of 
glutamate receptor system, ALA prevented neurotoxicity and seizure-like activity [31,32]. In 
vitro, ALA reduced hippocampal neuronal death induced by excitotoxic concentration of 
glutamate [33]. Finally, chronic intake of the “SR-3”, a fatty acid compound with LA/ALA 
ratio of 4, promoted neuroprotection against pentylenetetrazol-induced seizures in rat [34].  
Despite the fact that a direct link between ALA deficiency and cardiovascular disease has not 
been clearly demonstrated to date, epidemiological and correlations studies outlined its 
potential in cardiovascular diseases. Mediterranean and Japanese populations that consume 
foods rich in ALA are more resistant to cardiovascular disease [35].  
Djoussé et al. have investigated whether ALA consumption was associated with a lower risk 
of carotid atherosclerosis. Dietary ALA was inversely related to the thickness of carotid 
arteries, whereas fish-EPA and DHA consumption was not, suggesting that ALA could 
prevent the progression of atherosclerosis [36]. In addition to the protective effect of ALA 
against atherosclerotic plaque in coronary artery, dietary ALA prevented hypertension [36]. 
With regard to stroke, ALA plasma level increases seems to be correlated with a 37% 
decrease of the stroke risk [37]. These results indicate that ALA may play a role in the 
prevention or therapy of cardiovascular and neurovascular diseases. 
3. ALA and stroke 
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We have stressed the fact that the lack of omega-3 fatty acid could result in serious 
consequences for heart and brain health. As for cardiovascular diseases, many strokes caused 
by unhealthy diet and lifestyle could potentially be avoided. In this context, and in view of the 
recurrent failures in the development of drugs to prevent stroke, nutraceuticals or functional 
food enriched with omega-3 like ALA may represent a promising opportunity in prevention 
and perhaps also in treatment of neurovascular insults.  
3.1. ALA and the neurovascular unit 
Our interest in omega-3 originated from our discovery of their ability to activate the 
potassium channel TREK-1, regarded as a promising molecular target for new 
neuroprotective strategies [38]. Electrophysiology experiments revealed that ALA and its long 
chain derivatives EPA and DHA activate this channel, leading to cell hyperpolarization that 
may counteract lethal neuronal depolarizations associated with glutamate excitotoxicity, a key 
mechanism of stroke-induced neurodegeneration [32]. Although the protection may involve 
calcium, sodium and potassium conductance regulation, TREK-1 activation is compulsory for 
ALA-induced protection against stroke. In contrast, omega-6 PUFA like LA and AA seem 
less efficient in activating TREK-1 potassium channels and saturated fatty acids like 
palmitate, stearate and arachidate have no effects. In animal models reproducing the cerebral 
consequence of a myocardial arrest and epileptic seizure - a regular consequence in stroke -  
omega-3 acute injection reduced neuronal loss [31,32]. ALA cerebral protection is probably 
mediated by a direct effect on neurons, although ALA may exert its beneficial effect acting on 
the vascular compartment. Stroke injury also affects vascular functions altering the tonus of 
the injured artery. The loss of vasodilation capacity compromises the perfusion of the cerebral 
tissue. In vitro, ALA application onto basilar artery promotes its vasodilatation. This effect is 
specific to resistance arteries and does not extend to the carotid artery, explaining the absence 
of systemic effect on arterial pressure [39,40]. Cerebral blood flow measurement by laser 
Doppler revealed that injection of neuroprotective dose of ALA increased rates in rodents, as 
compared to the saturated fatty acids palmitate. ALA is not only beneficial to neurons but is 
also of great interest also for blood vessels. This implies that ALA could be beneficial for the 
whole neurovascular compartment, compared to a large number of typical stroke 
neuroprotective chemical molecules which only target neurons, and have failed in clinical 
trials. ALA might represent a successful neuroprotectant where many had tried and failed. 
3.2. ALA in an experimental model of focal ischemic stroke 
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In hypertensive rats highly predisposed to stroke, Shimokawa and colleagues highlighted that 
a diet enriched in perilla oil (60 % ALA) increases rat lifetime, compared to a diet enriched in 
sunflower oil (rich in linolenic acid) [41]. In humans, a clinical study conducted in 192 
patients revealed a strong correlation between ALA plasma levels in patients and a reduction 
in stroke susceptibility [37]. In humans, the occlusion of the sylvian artery represents about 
70% of stroke events. In a mouse model of ischemic stroke by the transient occlusion of the 
middle cerebral artery (MCAo), we investigated whether the intravenous injection of ALA 
could reduce the infarct volume. Our results show that ALA injection is effective when 
injected up to 6 hours after stroke onset, a time-frame probably compatible with a clinical 
setting. Those results are similar to those obtained with riluzole, a well described 
neuroprotectant, delivered in amyotrophic lateral sclerosis, suggesting that a nutraceutical like 
ALA could perform as a chemical.  Interestingly, a single ALA post-treatment did not 
improve long term survival, but several staggered post-treatment ALA injections improved 
the survival rates three fold measured one month after stroke onset [42]. This chronic ALA 
treatment when used as pre-treatment also reduces the post-ischemic infarct 24 hours after 
MCAo [33].  
3.3. ALA supplementation, synaptogenesis and neurogenesis 
The crucial evidence that ALA needs to be chronically injected to promote long term benefit 
suggests that ALA-induced protection against stroke is not exclusively built on its capacity to 
reduce glutamate-mediated excitotoxicity, a transient phenomenon that takes place during the 
first few hours post-ischemia. Since we have showed that omega-3 might stimulate 
endogenous protective pathways [31,33,43], it underlines the necesitty to dissect the 
subchronic ALA effects per se. We discovered that ALA treatment promotes neuronal 
plasticity, which may contribute to brain repair after stroke. Indeed this subchronic ALA 
treatment per se increases neurogenesis in the dentate gyrus. The neurogenesis accompanies 
an increase in synaptogenesis in the Dentate Gyrus, but also in the cortex as shown by an 
increase in the expression of proteins involved in synaptic function. ALA treatment induces 
VAMP-2 (Vesicle-Associated Membrane Protein 2, also called synaptobrevin) and SNAP-25 
(Synaptosomal-Associated Protein 25) expression, which are involved in vesicle budding in 
the synaptic active area. Synaptophysin-1, a protein of the vesicular membrane participating 
to presynaptic fusion pore involved in neurotransmitter release, is also upregulated as well as 
the glutamate transporter expression (VGLUT1 and VGLUT2). These effects are strongly 
correlated with an increase of BDNF (Brain Derived Neurotrophic Factor) observed both in 
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the brain of treated mice in vivo and in neural stem cells or in hippocampal cultures in vitro. 
Thus, the ALA protective effects mediated by a direct action on the neurovascular unit may 
also be supported by the stimulation of endogenous mechanisms involved in regeneration and 
recovery.  
3.3. Dietary ALA against stroke 
Since ALA supplementation by i.v. route is not relevant for prevention, we studied the 
possibility of providing ALA by a nutritional approach, by using an ALA-enriched vegetable 
oil such as rapeseed oil (9% ALA) to attain cerebral protection similar to that attained by 
ALA chronic injections. 
A 6-week diet enriched in ALA by a factor of three compared to regular chows and an omega-
6/omega-3 ratio blow 5- reduced cerebral infarct volume. The rapeseed oil-diet decreased the 
mortality rate three-fold and increased the spontaneous reperfusion probability measured 24 h 
post-MCAo [44]. This diet also decreased lipid peroxidation and oxidative stress associated 
with the brain ischemia. Beneficial effects were similar to those of parenteral supplementation 
and may be more efficient than those obtained by a supplementation with fish oil enriched in 
EPA/DHA, a paradigm still debated [44-47]. The rapeseed oil diet does not contain EPA and 
DHA; as mentioned previously, ALA is not sufficiently converted to DHA, so the ALA-
associated protection probably does not involve a bioconversion of ALA in EPA/DHA.  
4. Conclusion 
Classic neuroprotectors failed in stroke clinical trials. Researchers now focus on molecules 
acting on the whole neurovascular compartment and are searching for neuroprotectant- 
promoting protective mechanisms capable of acting at different intervals to counteract the 
different pathologic pathways. Then, it is tempting to speculate that ALA may adhere to the 
criteria of being a pleiotropic molecule (figure 3), able to block the deleterious neurotoxic 
signaling cascades in neurons, stimulate vascular function and also to stimulate defense and 
recovery mechanisms. The nutritional importance of ALA and its pleiotropic benefits should 
lead the scientific and medical community to focus interest in this particular omega 3 in other 
neurologic pathologies. 
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7. Legend of the figures 
Table 1: linoleic and alpha- linolenic acids composition of plant oil (g/100g), modified 
from Michaelsen et al. 2011 [20]. 
The type of omega-3 PUFA is a function of their origin (animal versus vegetable). Animal 
sources of omega-3 provide EPA/DHA and display an omega-3/omega-6 ratio in accordance 
to nutritional recommendations, but are often deprived of ALA. In contrast, vegetable sources 
of omega-3 are rich in ALA but not EPA/DHA. Only linseed, rapeseed and walnut oils offer a 
omega-3/omega-6 ratio lower than the recommended limit of 5. LA, linoleic acid; ALA, 
Alpha-linolenic acid; PUFA, polyunsaturated fatty acid. 
Figure 1: Initiation of stroke induced–pathologic signaling pathways differs in space and 
time, modified from Dirnagl 1999 [12] 
The x-axis reflects the evolution of the cascade over time, while the y-axis illustrates the 
impact of each event of the cascade on final outcome. Rapidly after the onset of the focal 
perfusion deficit, excitotoxic mechanisms trigger primarily neuron but also glia necrosis. In 
addition, excitotoxicity initiates a number of events leading to the demise of the brain tissue. 
This includes peri-infarct depolarizations and more delayed neurotoxicity mechanisms such as  
inflammation and programmed cell death. A brain region experiencing low rates of perfusion 
in which cells have lost their membrane potential terminally (core) is surrounded by an area in 
which intermediate perfusion prevails (penumbra) and cells depolarize intermittently (peri-
infarct depolarization). Note that from the onset of the focal perfusion deficit, the core and 
penumbra have different neurotoxic mechanistic dynamics in space and timing. 
Figure 2: Biosynthesis of the omega-6 and omega-3 PUFA.  
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The omega-6 and omega-3 families possess structural similarities. In mammals, the synthesis 
of the long chain derivatives from their distinct precursors LA and ALA involves the same 
enzymes (desaturases and elongase). This creates a competition between both families to 
develop the metabolic derivatives. LA is desaturated to form gamma-linolenic acid (GLA, 
18:3 omega-6) that in turn is elongated to form GLA (20:3 omega-6), the precursor of one 
series of prostaglandins (PGs). GLA is also converted to form AA (arachidonic acid, 20:4 
omega-6), the precursor of 2 series of PGs, thromboxanes (TXs) and 4 series leukotrienes 
(LTs). Similarly, ALA is converted to eicosapentaenoic acid (EPA, 20:5 omega-3), the 
precursor of 3 series of PGs, TXs, and 5 series LTs. EPA is also converted to form 
docosahexaenoic acid (DHA, 22:6 omega-3). Thus, excessive intake of LA can compromise 
eicosanoid acid (EPA) and docohexaenoic (DHA) production from ALA, the major long 
chains PUFA.  
Figure 3: ALA potential on different level of stroke-induced damages 
The schematic summarizes the different properties of ALA that could counteract stroke-
induced damage.  
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Vegetable oil Total 
fat 
Total 
PUFA 
LA ALA Ratio  
LA/ALA 
Sunflower oil 100.0 59.8 59.4 0.3 205/1 
Sesame oil 100.0 
 
41.2 40.7 0.5 85/1 
Palm oil 100.0 9.3 9.0 0.2 48/1 
Olive oil 100.0 
 
9.5 8.8 0.7 13/1 
Soybean oil 100.0 
 
62.3 55.1 7.2 8/1 
Canola oil 100.0 28.5 18.4 10.0 1.8/1 
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